Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Inclusion Criteria

• Subjects have provided informed consent/assent prior to initiation of any study-specific activities/procedures or subjects legally acceptable representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.
• Subjects with Ph-negative B-precursor ALL, with any of the following:
• Primary refractory after induction therapy or who had relapsed within 12 months of first remission or
• Relapsed within 12 months of receiving allogeneic hematopoietic stem cell transplantation (alloHSCT) or
• Relapsed or refractory after first salvage therapy or beyond
• > 5% blasts in bone marrow (by morphology)
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2
• Age ≥ 18 years at the time of informed consent

Exclusion Criteria

Disease Related

• Subjects with Ph-positive ALL
• Subjects with Burkitt´s Leukemia according to World Health Organization (WHO) classification.
• History or presence of clinically relevant CNS pathology as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, and psychosis
• Active ALL in the central nervous system (CNS) (confirmed by cerebrospinal fluid [CSF] analysis) or testes
• Isolated extramedullary disease
• Current active autoimmune disease or history of autoimmune disease with potential CNS involvement

Other Medical Conditions

• History of malignancy other than ALL within 5 years prior to start of protocol-specified therapy with the exception of:
• Malignancy treated with curative intent and with no known active disease present for 5 years before enrollment and felt to be at low risk for recurrence by the treating physician.
• Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
• Adequately treated cervical carcinoma in situ without evidence of disease.
• Adequately treated breast ductal carcinoma in situ without evidence of disease.
• Prostatic intraepithelial neoplasia without evidence of prostate cancer.
• Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive)

Medications or Other Treatments

• Autologous HSCT within 6 weeks prior to start of blinatumomab treatment
• AlloHSCT within 3 months prior to start of blinatumomab treatment
• Any active acute Graft-versus-Host Disease (GvHD), grade 2-4 according to the Glucksberg criteria or active chronic GvHD requiring systemic treatment
• Any systemic therapy against active GvHD within 2 weeks prior to start of blinatumomab treatment
• Cancer chemotherapy within 2 weeks prior to start of blinatumomab treatment (intrathecal chemotherapy and dexamethasone are allowed until start of blinatumomab treatment). In addition, any subject whose organ toxicity (excluding hematologic) from prior ALL treatment has not resolved to common terminology criteria for adverse events (CTCAE) ≤ grade 1.
• Radiotherapy within 2 weeks prior to start of blinatumomab treatment
• Immunotherapy (eg, rituximab) within 4 weeks prior to start of blinatumomab treatment
• Currently receiving treatment in another investigational device or drug study, or less than 4 weeks prior to start of blinatumomab treatment.
• Previous treatment with anti-CD19 therapy

General

• Known hypersensitivity to immunoglobulins or to any other component of the IMP formulation
• Pregnant women and women planning to become pregnant should not participate in this study. Subjects who are breast feeding prior to start of blinatumomab treatment may be enrolled if they stop breast feeding with breast milk produced during blinatumomab treatment and for an additional 48 hours after the last dose of blinatumomab.
• Male participants are not required to